A wrongful-death case involving the diet drug fenfluramine (fen-phen) that settled Jan. 27 in Middlesex, Mass., Superior Court was one of the first cases in the state to use a technique allowing lawyers from both sides to address juries directly throughout trial.
Seven trial days into what was projected to be a six- to eight-week trial, both parties in Linnen v. Wyeth-Ayerst Laboratories et al. reached a confidential settlement agreement. Neither side would comment on the settlement amount except to say a substantial portion would fund a foundation for the plaintiffs’ daughter who died of a heart condition after taking the prescription diet pill.
This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.
To view this content, please continue to their sites.
Not a Lexis Subscriber?
Subscribe Now
Not a Bloomberg Law Subscriber?
Subscribe Now
LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.
For questions call 1-877-256-2472 or contact us at [email protected]
